annual cash & cash equivalents:
$44.51M+$17.34M(+63.79%)Summary
- As of today (June 17, 2025), NAGE annual cash & cash equivalents is $44.51 million, with the most recent change of +$17.34 million (+63.79%) on December 1, 2024.
- During the last 3 years, NAGE annual cash & cash equivalents has risen by +$16.49 million (+58.85%).
- NAGE annual cash & cash equivalents is now -1.94% below its all-time high of $45.39 million, reached on December 1, 2017.
Performance
NAGE Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$55.46M+$10.96M(+24.62%)Summary
- As of today (June 17, 2025), NAGE quarterly cash & cash equivalents is $55.46 million, with the most recent change of +$10.96 million (+24.62%) on March 1, 2025.
- Over the past year, NAGE quarterly cash & cash equivalents has increased by +$28.05 million (+102.33%).
- NAGE quarterly cash & cash equivalents is now at all-time high.
Performance
NAGE quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
NAGE Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +63.8% | +102.3% |
| 3 y3 years | +58.9% | +166.7% |
| 5 y5 years | +139.1% | +313.7% |
NAGE Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +119.4% | at high | +324.6% |
| 5 y | 5-year | at high | +169.8% | at high | +324.6% |
| alltime | all time | -1.9% | >+9999.0% | at high | >+9999.0% |
NAGE Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $55.46M(+24.6%) |
| Dec 2024 | $44.51M(+63.8%) | $44.51M(+38.0%) |
| Sep 2024 | - | $32.25M(+16.3%) |
| Jun 2024 | - | $27.73M(+1.2%) |
| Mar 2024 | - | $27.41M(+0.9%) |
| Dec 2023 | $27.17M(+33.9%) | $27.17M(+2.1%) |
| Sep 2023 | - | $26.62M(+1.4%) |
| Jun 2023 | - | $26.25M(+14.2%) |
| Mar 2023 | - | $22.99M(+13.3%) |
| Dec 2022 | $20.29M(-27.6%) | $20.29M(+55.3%) |
| Sep 2022 | - | $13.06M(-22.6%) |
| Jun 2022 | - | $16.87M(-18.9%) |
| Mar 2022 | - | $20.79M(-25.8%) |
| Dec 2021 | $28.02M(+69.8%) | $28.02M(-14.8%) |
| Sep 2021 | - | $32.90M(-14.7%) |
| Jun 2021 | - | $38.58M(-13.3%) |
| Mar 2021 | - | $44.49M(+169.7%) |
| Dec 2020 | $16.50M(-11.4%) | $16.50M(+8.0%) |
| Sep 2020 | - | $15.28M(-18.3%) |
| Jun 2020 | - | $18.69M(+39.4%) |
| Mar 2020 | - | $13.41M(-28.0%) |
| Dec 2019 | $18.61M(-17.0%) | $18.61M(-0.4%) |
| Sep 2019 | - | $18.68M(-4.5%) |
| Jun 2019 | - | $19.56M(+2.3%) |
| Mar 2019 | - | $19.13M(-14.7%) |
| Dec 2018 | $22.42M(-50.6%) | $22.42M(-20.6%) |
| Sep 2018 | - | $28.21M(-15.5%) |
| Jun 2018 | - | $33.39M(-18.6%) |
| Mar 2018 | - | $41.04M(-9.6%) |
| Dec 2017 | $45.39M(+2663.6%) | $45.39M(+89.1%) |
| Sep 2017 | - | $24.00M(+69.7%) |
| Jun 2017 | - | $14.14M(+1092.7%) |
| Mar 2017 | - | $1.19M(-27.8%) |
| Dec 2016 | $1.64M | $1.64M(-27.5%) |
| Sep 2016 | - | $2.26M(-32.8%) |
| Jun 2016 | - | $3.37M(+12.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2016 | - | $3.00M(-46.0%) |
| Dec 2015 | $5.55M(+40.0%) | $5.55M(+17.9%) |
| Sep 2015 | - | $4.71M(-17.4%) |
| Jun 2015 | - | $5.70M(+77.2%) |
| Mar 2015 | - | $3.22M(-18.9%) |
| Dec 2014 | $3.96M(+75.3%) | $3.96M(+229.3%) |
| Sep 2014 | - | $1.20M(-6.0%) |
| Jun 2014 | - | $1.28M(-33.5%) |
| Mar 2014 | - | $1.92M(-14.9%) |
| Dec 2013 | $2.26M(+334.9%) | $2.26M(+108.0%) |
| Sep 2013 | - | $1.09M(+31.6%) |
| Jun 2013 | - | $826.60K(-14.5%) |
| Mar 2013 | - | $966.60K(+85.9%) |
| Dec 2012 | $520.00K(+23.8%) | $520.00K(-58.0%) |
| Sep 2012 | - | $1.24M(-44.1%) |
| Jun 2012 | - | $2.21M(-61.9%) |
| Mar 2012 | - | $5.81M(+1281.5%) |
| Dec 2011 | $420.20K(-81.1%) | $420.20K(-79.7%) |
| Sep 2011 | - | $2.07M(+1.2%) |
| Jun 2011 | - | $2.04M(-29.4%) |
| Mar 2011 | - | $2.90M(+30.1%) |
| Dec 2010 | $2.23M(+372.3%) | $2.23M(-25.4%) |
| Sep 2010 | - | $2.99M(-11.7%) |
| Jun 2010 | - | $3.38M(+527.8%) |
| Mar 2010 | - | $538.70K(+14.3%) |
| Dec 2009 | $471.40K(-58.1%) | $471.40K(-6.0%) |
| Sep 2009 | - | $501.40K(-17.3%) |
| Jun 2009 | - | $606.60K(-28.0%) |
| Mar 2009 | - | $843.00K(-25.1%) |
| Dec 2008 | $1.13M(>+9900.0%) | $1.13M(-53.5%) |
| Sep 2008 | - | $2.42M(+0.2%) |
| Jun 2008 | - | $2.42M(>+9900.0%) |
| Feb 2008 | - | $600.00(0.0%) |
| Nov 2007 | $600.00 | $600.00(-85.7%) |
| Aug 2007 | - | $4200.00(-50.6%) |
| May 2007 | - | $8500.00(-19.8%) |
| Feb 2007 | - | $10.60K |
FAQ
- What is Niagen Bioscience annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Niagen Bioscience?
- What is Niagen Bioscience annual cash & cash equivalents year-on-year change?
- What is Niagen Bioscience quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for Niagen Bioscience?
- What is Niagen Bioscience quarterly cash & cash equivalents year-on-year change?
What is Niagen Bioscience annual cash & cash equivalents?
The current annual cash & cash equivalents of NAGE is $44.51M
What is the all time high annual cash & cash equivalents for Niagen Bioscience?
Niagen Bioscience all-time high annual cash & cash equivalents is $45.39M
What is Niagen Bioscience annual cash & cash equivalents year-on-year change?
Over the past year, NAGE annual cash & cash equivalents has changed by +$17.34M (+63.79%)
What is Niagen Bioscience quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of NAGE is $55.46M
What is the all time high quarterly cash & cash equivalents for Niagen Bioscience?
Niagen Bioscience all-time high quarterly cash & cash equivalents is $55.46M
What is Niagen Bioscience quarterly cash & cash equivalents year-on-year change?
Over the past year, NAGE quarterly cash & cash equivalents has changed by +$28.05M (+102.33%)